Group 1 - Lisata Therapeutics has initiated a global product license agreement with Catalent, allowing Catalent to incorporate Lisata's certepetide into antibody-drug conjugates (ADCs) using its SMARTag technology platform [1][2] - The partnership is seen as a validation of certepetide's versatility and positions Lisata's technology within a leading ADC platform [1] - Catalent has acquired non-exclusive rights to develop and commercialize products utilizing certepetide and its analogs, highlighting the broad potential of certepetide [2]